Plain-English translation of NCT04868604 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The treatment uses a radioactive form of copper that targets cancer cells. Researchers want to understand how safe this medication is and whether it effectively shrinks tumors.
Men with advanced prostate cancer that has become resistant to hormone therapy have limited treatment options, and many need new approaches to slow their cancer's growth. This trial aims to develop a new tool that could help these patients by directly targeting cancer cells while minimizing harm to healthy tissue.
You likely qualify if…
You likely don't qualify if…
You will receive several injections of the radioactive copper medication over time—the exact number depends on which phase of the study you join. You'll have imaging scans done before and after treatment to see how well the medication is working and to monitor for side effects. Throughout the trial, you'll have blood tests and check-ins with your doctor to make sure the treatment is safe.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States